Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si (NASDAQ: QSI) presented significant advancements in its protein sequencing technology at the Next-Generation Protein Analysis Conference. Dr. Brian Reed announced the ability to cover over 70% of the human proteome and identify up to 90% of proteins, including vital post-translational modifications. The company's Platinum™ Protein Sequencing Platform is on track for commercialization later this year, enhancing research capabilities across various medical fields like oncology and cardiology. For more information, visit Quantum-Si's website.
Quantum-Si Incorporated (Nasdaq: QSI) announced its participation in the 2022 Jefferies Healthcare Conference from June 8-10 in New York, NY. The company's management will present on June 10 at 8:30 am ET. A live and archived webcast of the event will be accessible in the Investors section of Quantum-Si's website. Quantum-Si is pioneering single molecule protein sequencing technology to advance drug discovery and diagnostics, utilizing a unique semiconductor chip for enhanced proteomic research.
Quantum-Si Incorporated (Nasdaq: QSI) announced its participation in the Next-Generation Protein Analysis and Detection Conference in Ghent, Belgium, on May 30-31, 2022. Dr. Brian Reed, Head of Research, will present on May 31 at 2:40 PM CEST, discussing advancements in real-time dynamic single-molecule protein sequencing. The conference aims to highlight innovations in proteomics, a field Quantum-Si is transforming with its novel semiconductor chip technology. The presentation's abstract will be available until August 30, 2022, for registered attendees.
Quantum-Si Incorporated (NASDAQ: QSI) is set to present at the 2022 UBS Global Healthcare Conference from May 23-25, 2022, at the Lotte New York Palace. The presentation is scheduled for May 23, 2022, at 3:30 pm ET. Quantum-Si specializes in single molecule protein sequencing and is advancing the field of proteomics with innovative semiconductor technology. The event will be accessible via a live and archived webcast on the Quantum-Si Investors website.
Quantum-Si (Nasdaq: QSI) announced its first-quarter financial results for 2022, reporting a net loss of $35.2 million, up from $11.8 million in Q1 2021. Research and development expenses increased significantly to $18.8 million, driven by higher personnel costs. The company held $434.8 million in cash and marketable securities, ensuring adequate funding for future initiatives. Quantum-Si also made progress in technology transfer and announced the appointment of Patrick Schneider as President & COO, aiming for a launch in the second half of 2022.
Quantum-Si Incorporated (NASDAQ: QSI) appointed Patrick Schneider, Ph.D., as President and COO, succeeding Michael McKenna, who will stay on as Executive VP of Product Development. Schneider brings over 25 years of experience in life sciences, previously serving at MilliporeSigma, where he oversaw strategy and business development. Interim CEO Jonathan Rothberg expressed confidence in Schneider's leadership to drive the company's ambitious plans for next-generation protein sequencing. Quantum-Si aims to revolutionize proteomics with its innovative semiconductor chip technology.
Tesseract Health has appointed Michael McConnell, MD, MSEE, as Head of Cardiovascular and Digital Health, strengthening its leadership under CEO Vicky Demas. Dr. McConnell brings expertise from Google Health and aims to guide the development of cardiovascular health products using Tesseract's non-invasive technology. The company is focused on democratizing health screening and aims to innovate ocular health diagnostics. Tesseract is part of 4Catalyzer, which includes companies like Butterfly Network (NYSE: BFLY), Quantum-Si (NASDAQ: QSI), and Hyperfine (NASDAQ: HYPR).
Quantum-Si Incorporated (NASDAQ: QSI), a leader in single molecule protein sequencing, will disclose its first quarter 2022 financial results post-market on May 9, 2022. A conference call for discussing these results and providing a business update is scheduled for 4:30 p.m. ET on the same day. The company's innovative technologies aim to transform proteomics by utilizing a unique semiconductor chip to enhance drug discovery and diagnostics.
Quantum-Si Incorporated (NASDAQ: QSI) announced participation in the B. Riley Disruptive Biotech Enabling Technologies Virtual Mini Conference. Scheduled for April 7, 2022, at 10:20 am ET, the presentation will focus on the company's innovative approach to single molecule protein sequencing aimed at revolutionizing proteomics and advancing drug discovery. Interested listeners should contact their B. Riley Securities representatives for access. Quantum-Si’s technology leverages a unique semiconductor chip for enhanced proteomic research.
Quantum-Si (Nasdaq: QSI) reported its Q4 and fiscal year 2021 results, revealing significant increases in operating expenses totaling $27.8 million in Q4, leading to a net loss of $29.4 million. For the fiscal year, total net loss reached $95.0 million, up from $36.6 million in 2020. The company ended the year with $471.3 million in cash and equivalents, positioning it well for upcoming product launches in 2022. They formed a new Scientific Advisory Board, expanded staff from 72 to 153, and entered strategic partnerships to enhance research applications.